-
Development of quality indicators for pregnancy and childbirth in patients with systemic lupus erythematosus Mod. Rheumatol. (IF 2.2) Pub Date : 2024-04-09 Mika Hatano, Nobuyuki Yajima, Ryo Yanai, Sho Ishii, Yasushi Tsujimoto, Teruhisa Azuma, Tatsuya Atsumi, Yuko Kaneko, Hideto Kameda, Masataka Kuwana, Yoshiya Tanaka, Shiori Nakagawa, Ayako Nakajima, Yuri Hiramatsu, Daisuke Fujita, Takako Miyamae, Atsuko Murashima
Objectives A quality indicator (QI) for the treatment of systemic lupus erythematosus (SLE) during pregnancy and childbirth that is useful for sharing standard treatment policies has not yet been developed. This study aimed to develop a QI for SLE associated with pregnancy and childbirth. Methods To identify candidate QIs, we conducted a systematic literature review on the development of QIs for SLE
-
Interferons Dominate Damage and Activity in Juvenile Scleroderma Mod. Rheumatol. (IF 2.2) Pub Date : 2024-04-06 Hulya Kose, Abdurrahman Simsek, Muhammed Ali Kizmaz, Tugce Bozkurt, Ferdi Ozturk, Sukru Cekic, Ferah Budak, Hayriye Sarıcaoglu, Sara Sebnem Kilic
Juvenile scleroderma is a heterogeneous group of diseases associated with sclerotic skin lesions, grouped as juvenile systemic sclerosis systemic sclerosis) and juvenile localized scleroderma. This study aims to measure the cytokine and chemokine levels involved in interferon signaling in patients with juvenile scleroderma and determine their correlation with disease severity. METHOD: Twenty-nine juvenile
-
Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) using a Japanese claims database Mod. Rheumatol. (IF 2.2) Pub Date : 2024-04-06 Natsuko Tokushige, Yasuhiro Hayashi, Junichi Omura, Tatsunori Jinnai, Tatsuya Atsumi
Objectives: To investigate the diagnostic and therapeutic landscape for patients with connective tissue disease (CTD) and CTD-associated pulmonary arterial hypertension (CTD-PAH) in acute-care general hospitals in Japan. Methods: We conducted a retrospective cohort study by analysing the Medical Data Vision (MDV) database from April 2008 and September 2020. CTD patients who prescribed immunosuppressants
-
The real-world clinical decisions of physicians in the management of Takayasu arteritis and giant cell arteritis in Japan: A cross-sectional web-questionnaire survey Mod. Rheumatol. (IF 2.2) Pub Date : 2024-04-04 Yoshiyuki Abe, Takao Fujii, Yoshia Miyawaki, Takahiko Sugihara, Haruhito A Uchida, Yasuhiro Maejima, Yoshiko Watanabe, Takuya Hashimoto, Takako Miyamae, Yoshikazu Nakaoka, Masayoshi Harigai, Naoto Tamura
Objectives: To access the real-world clinical management of physicians who treat Takayasu arteritis (TAK) and giant cell arteritis (GCA) after the publication of the Japanese Circulation Society (JCS) 2017 Guidelines for the Management of Vasculitis Syndrome. Methods: This descriptive, cross-sectional study utilized self-administered electronic questionnaires, which were answered in February 2022 by
-
Cluster analysis defines four groups of Japanese patients with adult-onset Still’s disease Mod. Rheumatol. (IF 2.2) Pub Date : 2024-04-02 Yuri Shirahama, Ayako Kokuzawa, Yusuke Yamauchi, Yohei Kirino, Hideto Nagai, Yasushi Inoue, Toshiyuki Ota, Yutaka Chifu, Hiroki Mitoma, Mitsuteru Akahoshi, Mariko Sakai, Akihito Maruyama, Akihide Ohta, Masahiro Iwamoto, Yoshifumi Tada
Objectives To define groups and characterize differences in the prognosis of patients with adult-onset Still’s disease (AOSD). Methods We performed a retrospective cohort study. Patients with AOSD were grouped using hierarchical unsupervised cluster analysis according to age, sex, clinical features, and laboratory data. The primary endpoints were overall survival and drug-free remission rate. Results
-
Risk factors for serious infections and infection-related mortality in patients with microscopic polyangiitis: Multicentre REVEAL cohort study Mod. Rheumatol. (IF 2.2) Pub Date : 2024-04-02 Atsushi Manabe, Keiichiro Kadoba, Ryosuke Hiwa, Takuya Kotani, Mikihito Shoji, Mirei Shirakashi, Hideaki Tsuji, Koji Kitagori, Shuji Akizuki, Ran Nakashima, Hajime Yoshifuji, Wataru Yamamoto, Ayana Okazaki, Shogo Matsuda, Takaho Gon, Ryu Watanabe, Motomu Hashimoto, Akio Morinobu
Objective Infections are a critical concern for patients with microscopic polyangiitis (MPA). This study aimed to identify the risk factors associated with serious infections (SIs) and infection-related mortality in patients with MPA, as well as the effect of glucocorticoid (GC) dose tapering on these outcomes. Methods This multicentre, retrospective, and observational study utilised data from a cohort
-
Opportunities and challenges of lupus care in Latin America, the Middle East, and Asia-Pacific: A call to action Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-26 Eduardo Mysler, Odirlei Andre Monticielo, Ibrahim Abdulrazaq Al-Homood, Chak Sing Lau, Heselynn Hussein, Yi-Hsing Chen
Lupus remains a disease with a low prioritisation in the national agendas of many countries in Latin America, the Middle East, and Asia-Pacific, where there is a dearth of rheumatologists and limited access to new or even standard lupus treatments. There is thus an important need for education, advocacy, and outreach to prioritise lupus in these regions to ensure that patients receive the care they
-
Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-22 Tomoya Kawakami, Sho Masui, Akira Onishi, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami, Koichi Murata, Masao Tanaka, Takashi Shimada, Shunsaku Nakagawa, Shuichi Matsuda, Akio Morinobu, Tomohiro Terada, Atsushi Yonezawa
Objectives Biosimilars are anticipated to be widely used in the treatment of rheumatoid arthritis (RA), owing to their cost efficiency; LBEC0101 was the first etanercept (ETN) biosimilar approved in Japan. However, there are limited real-world data comparing its safety and effectiveness with those of a reference product. Methods This study used data from the Kyoto University Rheumatoid Arthritis Management
-
Consensus statement on the management of late-onset rheumatoid arthritis Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-21 Masayo Kojima, Takahiko Sugihara, Yutaka Kawahito, Toshihisa Kojima, Yuko Kaneko, Hajime Ishikawa, Asami Abe, Kazuo Matsui, Shintaro Hirata, Mitsumasa Kishimoto, Eiichi Tanaka, Akio Morinobu, Motomu Hashimoto, Isao Matsushita, Toshihiko Hidaka, Toshihiro Matsui, Keiichiro Nishida, Shuji Asai, Hiromu Ito, Ryozo Harada, Masayoshi Harigai
Objectives Late-onset rheumatoid arthritis (LORA), which has been increasing in recent years, lacks evidence for initial treatment. Japanese rheumatology experts recognized this gap and addressed it by developing consensus statements on the first clinical application of LORA. Methods These statements were created following an introductory discussion about treatment fundamentals, which included a review
-
Comparison of effectiveness of methotrexate in patients with late-onset versus younger-onset rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J) Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-16 Shuji Asai, Mochihito Suzuki, Ryota Hara, Yuji Hirano, Satomi Nagamine, Tetsuya Kaneko, Takahito Suto, Tadashi Okano, Yutaka Yoshioka, Makoto Hirao, Hiroki Wakabayashi, Takayoshi Fujibayashi, Tatsuo Watanabe, Yuya Takakubo, Hajime Ishikawa, Yoshihisa Nasu, Toki Takemoto, Takefumi Kato, Eiji Torikai, Kensuke Koyama, Hideki Takagi, Toshifumi Fujiwara, Yasumori Sobue, Yoshifumi Ohashi, Tsuyoshi Nishiume
Objective To compare the effectiveness of methotrexate (MTX) as initial therapy in patients with late-onset and younger-onset rheumatoid arthritis (LORA and YORA). Methods Of 114 patients with YORA and 96 patients with LORA, defined as RA occurring at ≥65 years of age, enrolled in a multicentre RA inception cohort study, 71 and 66 patients who had been followed up to 6 months after starting MTX treatment
-
Significant association of HLA-A26 with uveitis and gastrointestinal involvement in patients with Behçet’s disease in a multicenter study Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-14 Tomoya Nakajima, Hideaki Tsuji, Ryuta Inaba, Rintaro Saito, Keisuke Nishimura, Akio Morinobu
Objectives: Specific HLA haplotypes are associated with Behçet’s disease (BD). Because the effects of HLA-A26 and its combination with HLA-B51 on organ involvement in BD have not been well demonstrated, we aimed to examine them. Methods: This multicenter, cross-sectional, observational study enrolled patients with BD who visited Kyoto University Hospital between 2018 and 2021 or Kurashiki Central Hospital
-
Disease-modifying anti-rheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-07 Naohisa Miyakawa, Katsuki Tsuritani, Bruno Casaes Teixeira, Keishi Fujio
Objectives: We evaluated the medication selection and clinical characteristics of rheumatoid arthritis (RA) patients who started treatment with/without methotrexate (using biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors [JAKi] instead) in Japan. Methods: Using a Japanese hospital-based administrative claims database, RA patients who received treatment (abatacept, interleukin-6
-
Osteoporosis and Osteopenia in patients with psoriatic arthritis: a single-center retrospective study Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-05 Kenji Takami, Mari Higashiyama, Shigeyoshi Tsuji
Objective: It is known that fracture risk is increased in patients with psoriatic arthritis (PsA), however, there is no consensus on the association with osteoporosis. The purpose of this study was to elicit the rate of osteoporosis and the risk factors of osteoporosis in patients with PsA at our institution. Methods: The data in this study were extracted from 163 patients with PsA. Osteoporosis and
-
LncRNA OIP5-AS1 promotes mitophagy to alleviate osteoarthritis by up-regulating PPAR-γ to activate AMPK/Akt/mTOR pathway Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-05 Zhilu Sun, Jie Tang, Ting You, Bihong Zhang, Yu Liu, Jing Liu
Background: Osteoarthritis (OA) is the most common chronic joint degenerative disease. Mitophagy is closely related to OA pathogenesis. Herein, we investigated the role of lncRNA OIP5-AS1 in regulating mitophagy during OA. Methods: RT-qPCR and Western blotting were utilized to analyze gene and protein levels. RIP and RNA pull down verified the relationship between OIP5-AS1, FUS and PPAR-γ. CCK-8 assay
-
Pregnancy-related issues from the perspective of patients with inflammatory rheumatic diseases – Results from a survey of the members of the National Association for Inflammatory Rheumatic Diseases Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-05 Atsuko Murashima, Kayoko Kaneko, Hiroshi Oguro, Yukiko Mori, Mikako Goto, Shuko Mishima, Tatsuhiko Anzai, Kunihiko Takahashi
Objectives: This study aimed to clarify the issues related to pregnancy in patients with inflammatory rheumatic diseases (RDs) and to provide useful information for developing medical services from patients’ perspectives. Methods: A survey involving approximately 5,000 members of the Patients Association for Collagen Vascular Diseases Japan was conducted using a questionnaire that was sent and returned
-
Systematic review for the treatment of older rheumatoid arthritis patients informing the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-04 Takahiko Sugihara, Yutaka Kawahito, Yuko Kaneko, Eiichi Tanaka, Ryo Yanai, Nobuyuki Yajima, Masayo Kojima, Masayoshi Harigai
Objectives: To update an evidence base informing the 2024 JCR clinical practice guidelines (CPGs) for the management of rheumatoid arthritis (RA) in older adults. Methods: Four clinical questions (CQs) regarding efficacy and safety of drug treatment were evaluated, with CQ1 addressing methotrexate (MTX), CQ2 biological disease-modifying antirheumatic drugs (bDMARDs), CQ3 Janus kinase (JAK) inhibitors
-
Evaluation of Medication Withdrawal in Patients with Non-systemic Juvenile Idiopathic Arthritis in Japan Using a Web-based Survey Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-02 Takasuke Ebato, Takayuki Kishi, Keiji Akamine, Tomo Nozawa, Tomoyuki Imagawa, Yuki Bando, Takako Miyamae
Objective: Although treatments for juvenile idiopathic arthritis (JIA) have seen considerable advancements, there remains a lack of clear guidelines on withdrawing medications. This study aimed to investigate the current strategies for discontinuing non-systemic JIA treatment. Methods: A web-based questionnaire was distributed to Pediatric Rheumatology Association of Japan members. Results: According
-
Short-term efficacy and limitations of foot care in patients with rheumatoid arthritis Mod. Rheumatol. (IF 2.2) Pub Date : 2024-03-02 Koichiro Yano, Katsunori Ikari, Emiko Shiraki, Mitsuki Midorikawa, Masami Maeda, Kazuya Kubo, Yasushi Kuwahara, Ken Okazaki
Objectives Foot and ankle impairments are major issues in patients with rheumatoid arthritis (RA). Foot deformities often lead to skin disorders, such as callosities, ingrown toenails, and interdigital tinea pedis. This study was aimed at investigating the efficacy and limitations of foot care by experts in patients with RA. Methods Thirty-one patients with RA who began receiving foot care from nurses
-
Nationwide epidemiological survey of polyarteritis nodosa in Japan in 2020 Mod. Rheumatol. (IF 2.2) Pub Date : 2024-02-12 Mai Kawazoe, Toshihiro Nanki, Keigo Saeki, Hideki Ishikawa, Yoshikazu Nakamura, Soko Kawashima, Shuichi Ito, Masanari Kodera, Naoko Konda, Shinya Kaname, Masayoshi Harigai
Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that predominantly affects medium-sized arteries. With advances in our understanding of the pathogenesis and classification of vasculitis, PAN and microscopic polyangiitis (MPA), a disease of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), were separated from the group of diseases previously diagnosed as periarteritis
-
Characteristics of anti-melanoma differentiation associated gene 5 antibody-positive dermatomyositis with thrombotic microangiopathy Mod. Rheumatol. (IF 2.2) Pub Date : 2024-02-12 Toshiyuki Shiki Ushijima, Toshihiko Komai, Shinji Izuka, Hirofumi Shoda, Keishi Fujio
Objectives: Anti-melanoma differentiation associated gene 5 antibody (anti-MDA5 Ab)-positive dermatomyositis (DM) is representative of rapidly progressive interstitial pneumonia. However, its association with thrombotic microangiopathy (TMA), characterized by thrombocytopenia, hemolytic anemia, and organ dysfunction, has not been defined. This study aimed to elucidate the characteristics of anti-MDA5
-
Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study Mod. Rheumatol. (IF 2.2) Pub Date : 2024-02-01 Kai-Chun Wang, Yi-Syuan Sun, Hung-Cheng Tsai, Hsien-Tzung Liao, Chien-Chih Lai, Wei-Sheng Chen, Ling-Ying Lu, Ming-Han Chen
Objectives To assess the link between the administration of biologic disease-modifying antirheumatic drugs (bDMARDs) and the risk of malignancy in human leukocyte antigen B27 (HLA-B27)-positive patients with ankylosing spondylitis (AS) experiencing sustained inflammation. Methods Between 2006 and 2021, 1445 HLA-B27-positive patients with AS were retrospectively evaluated. Among them, 112 patients required
-
Examination of Prognostic Factors in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Mod. Rheumatol. (IF 2.2) Pub Date : 2024-02-01 Suzuna Sugi, Masaki Tominaga, Shinjiro Kaieda, Kiminori Fujimoto, Tomonori Chikasue, Takuma Koga, Yuri Hasuo, Erina Iwanaga, Kenta Murotani, Jamie Kristen T Lim, Hiroaki Ida, Tomotaka Kawayama, Tomoaki Hoshino
Objective. This study investigated the prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM). Methods. This study analysed 34 MDA5-DM cases (20 and 14 in the survival and death groups, respectively) encountered at Kurume University between 2008 and 2021. The clinical, physiological, and computed tomography findings, pulmonary function, and
-
Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab Mod. Rheumatol. (IF 2.2) Pub Date : 2024-02-01 Kyosuke Hattori, Yasuhide Kanayama
Objectives The present study aimed to investigate the effectiveness of treatment with romosozumab for one year and association between bone turnover markers and changes in bone mineral density (BMD) in patients with postmenopausal osteoporosis (PMO). Methods Participants were 53 treatment-naïve PMO patients. Correlations of percent changes (Δ) in lumbar (L) and total hip (TH) BMD 12 months after initiating
-
Trends in Treatment for Patients with Late-onset Rheumatoid Arthritis in Japan: Data from the NinJa Study Mod. Rheumatol. (IF 2.2) Pub Date : 2024-01-22 Toshihiro Matsui, Tomoya Yoshida, Takahiro Nishino, Shigeru Yoshizawa, Tetsuji Sawada, Shigeto Tohma
Objectives To investigate trends in the treatment of patients with late-onset rheumatoid arthritis (LORA) using data from the National Database of Rheumatic Diseases in Japan (NinJa). Methods Patients registered in the NinJa were classified according to disease onset: at <65 years (young-onset rheumatoid arthritis [YORA]); at 65–74 years (early LORA); and at ≥75 years (late LORA). Chronological changes
-
Early full weight-bearing and gait exercise after cemented total ankle arthroplasty with modified antero-lateral approach Mod. Rheumatol. (IF 2.2) Pub Date : 2024-01-22 Manabu Sakata, Makoto Hirao, Takaaki Noguchi, Gensuke Okamura, Yusei Higuchi, Yuki Tabuse, Yuki Etani, Kosuke Ebina, Hideki Tsuboi, Akira Miyama, Koichiro Takahi, Kenji Takami, Shigeyoshi Tsuji, Seiji Okada, Jun Hashimoto
Background: According to the conventional postoperative procedure after total ankle arthroplasty (TAA) against end-stage osteoarthritis (OA) and rheumatoid arthritis (RA), mobilization and weight-bearing is currently started after completion of wound healing. Recently, early mobilization for dorsiflexion after TAA with modified antero-lateral approach was reported to be feasible and safe. To investigate
-
Characteristics of patients presenting with concomitant carpal tunnel syndrome at the initial diagnosis with rheumatoid arthritis Mod. Rheumatol. (IF 2.2) Pub Date : 2024-01-21 Taiki Nakamura, Keita Nagira, Naoki Nakagawa, Yuta Takasu, Koji Ishida, Masako Hayashibara, Hiroshi Hagino, Hideki Nagashima
Objective To investigate the clinical characteristics of patients who presented with concomitant carpal tunnel syndrome (CTS) at the initial diagnosis with rheumatoid arthritis (RA). Methods We analyzed patients with newly diagnosed RA at a single institution between 2012 and 2021. Patient demographic and laboratory data, the 2010 ACR/EULAR classification criteria, and the duration from the initial
-
Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study Mod. Rheumatol. (IF 2.2) Pub Date : 2024-01-16 Naoki Iwamoto, Shuntaro Sato, Kaori Furukawa, Toru Michitsuji, Kazuteru Shiraishi, Kounosuke Watanabe, Ko Chiba, Makoto Osaki, Atsushi Kawakami
Objectives: To clarify changes in serum cytokines, chemokines, and bone-related factors during denosumab treatment in rheumatoid arthritis (RA) patients. Methods: This was a post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Patients were randomly assigned to continue treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) plus receive
-
Large language model may assist diagnosis of SAPHO syndrome by bone scintigraphy Mod. Rheumatol. (IF 2.2) Pub Date : 2023-12-28 Yu Mori, Takuya Izumiyama, Ryuichi Kanabuchi, Naoko Mori, Toshimi Aizawa
Objective: In this study, we employed a large language model to evaluate the diagnostic efficacy of radiology reports of bone scintigraphy in the context of identifying SAPHO syndrome, and further examined the potential of such a model to augment the diagnostic procedure. Methods: Imaging data and clinical information of 151 patients (105/46 women/men, mean age: 53.5 years) who underwent bone scintigraphy
-
Preoperative radiographs underdiagnose the severity of lateral femoral and medial trochlear cartilage damage in varus osteoarthritis knees Mod. Rheumatol. (IF 2.2) Pub Date : 2023-12-21 Takahiro Maeda, Shinichi Kuriyama, Takayuki Ito, Naoki Umatani, Kohei Nishitani, Shinichiro Nakamura, Shuichi Matsuda
Objective: This study evaluated whether preoperative radiographs accurately predicted intra-articular cartilage damage in varus knees. Methods: The study assessed 181 knees in 156 patients who underwent total knee arthroplasty. Cartilage damage was graded by two examiners with the International Cartilage Repair Society (ICRS) classification; one used knee radiographs and the other used intraoperative
-
Complications After Orthopedic Surgeries in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors: a Retrospective Observational Study Mod. Rheumatol. (IF 2.2) Pub Date : 2023-12-19 Hirofumi Bekki, Tomomitsu Hashiguchi, Seiichi Kawamura, Masakazu Kondo, Hidetoshi Tsushima, Koji Sakuraba, Masamitsu Hara, Masanari Ohta, Hisaaki Miyahara, Yasuharu Nakashima, Jun-ichi Fukushi
Objectives: The current study compared the outcome after orthopedic surgeries in patients with RA receiving JAKi versus biologic disease-modifying anti-rheumatic drugs (bDMARDs). Methods: This was a retrospective observational study of Japanese patients with RA. Sixty-two patients with RA using JAKi preoperatively underwent orthopedic surgeries. Using propensity score matching, these 62 patients were
-
Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2) Mod. Rheumatol. (IF 2.2) Pub Date : 2023-12-16 Yoshiya Tanaka, Tsutomu Takeuchi, Yoshiaki Morita, Yuichiro Kaneko, Wataru Terada
Objectives This post hoc analysis of the RAJ2 study assessed long-term safety and effectiveness of peficitinib 100 mg/day for treatment of rheumatoid arthritis. Methods Eligible patients previously completed two Phase 3 (RAJ3 and RAJ4) studies of peficitinib in Asia. All patients received peficitinib 100 mg/day at RAJ2 Week (W)0; dose change to 50 mg/day or 150 mg/day was permitted. Safety endpoints
-
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A 48-week interim analysis of the MARS study Mod. Rheumatol. (IF 2.2) Pub Date : 2023-12-15 Tomonori Ishii, Hideaki Kunishige, Tamami Kobayashi, Etsuko Hayashi, Masaki Komatsubara, Takeo Ishii, Rafael Alfonso-Cristancho, Jun Tamaoki, Peter Howarth
Objectives The objective of the study is to assess real-world, long-term safety/effectiveness of mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA) in Japan. Methods The Mepolizumab long-term study to Assess Real-world Safety and effectiveness of EGPA in Japan (MARS) (GSK ID: 213684/NCT04551989) is an ongoing 96-week study of patients with EGPA who received four-weekly mepolizumab
-
Safety and effectiveness of denosumab in Japanese patients with rheumatoid arthritis: a 2-year post-marketing surveillance study Mod. Rheumatol. (IF 2.2) Pub Date : 2023-12-04 Yoshiya Tanaka, Hideki Mizutani, Kunimitsu Fujii, Naoki Okubo
Objectives To investigate the 2-year safety and effectiveness of denosumab 60 mg in patients with rheumatoid arthritis (RA) in clinical practice in Japan. Methods This 2-year, prospective, observational cohort study included patients who initiated treatment with denosumab 60 mg for the progression of bone erosion associated with RA. Key endpoints were adverse drug reactions (ADRs), progression of bone
-
The dietary acid load is associated with disease severity in psoriatic arthritis (PsA) Mod. Rheumatol. (IF 2.2) Pub Date : 2023-11-12 Sümeyra Öteleş, Gizem Ayan, Mustafa Ekici, Edibe Ünal, Pelin Bilgiç, Umut Kalyoncu
Objectives An acidogenic diet, by disrupting the blood pH equilibrium, can contribute to metabolic acidosis and lead to inflammation. Therefore, we hypothesized that dietary acid load (DAL) increases disease activity and inflammation in PsA patients. Methods This study was conducted with 58 obese/overweight patients, aged 20-65 years. Dietary intake was assessed using a 3-consecutive-day 24-hour recall
-
Healthcare resource utilisation and economic burden of patients with adequate and inadequate responses to biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis in Japan. Mod. Rheumatol. (IF 2.2) Pub Date : 2023-11-09 Kei Ikeda,Yuko Kaneko,Yuki Tsujita,Isao Kawaguchi,Jayeshkumar Patel,Toru Yamazaki,Siran Fang,Yutaka Kawahito
OBJECTIVE To compare healthcare resource utilisation (HCRU) and direct costs between responders vs non-responders to advanced therapies for rheumatoid arthritis (RA). METHODS Patients initiating ≥1 advanced therapy (Oct 2018-Sept 2019) with ≥1 RA claim (6-month pre-index period), ≥2 RA claims (any period), and ≥12 months follow-up were identified from the Medical Data Vision claims database. HCRU and
-
Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: real-world database analysis Mod. Rheumatol. (IF 2.2) Pub Date : 2023-11-06 Ken-ei Sada, Takeo Suzuki, Sandra Joksaite, Shinyoung Ju, John Logie, George Mu, Jeremiah Hwee, Hideaki Kunishige, Takeo Ishii, Amit Adlak, Harini Vadlamudi, Rafael Alfonso-Cristancho
Objectives Report the prevalence of eosinophilic granulomatosis with polyangiitis (EGPA) and describe oral corticosteroid (OCS) use and disease burden before and after mepolizumab approval in 2018 for EGPA in Japan. Methods Two retrospective studies (GSK IDs: 218083; 218084) used two databases: 1) the JMDC insurer database (Japanese health insurer claims) was used to report annual EGPA prevalence and
-
Association between matrix metalloprotease-3 levels and radiographic progression in patients with RA: a post hoc analysis from a Japanese phase 3 clinical trial of peficitinib (RAJ4). Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-30 Tsutomu Takeuchi,Yoshiya Tanaka,Yoshiaki Morita,Daisuke Kato,Yuichiro Kaneko,Wataru Terada
-
Clinical investigation for the mechanisms of anaphylactic symptoms in osteoarthritis patients after diclofenac etalhyaluronate administration Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-20 Yoshihiro Nishida, Akiko Yagami, Shuhei Takada, Dai Muramatsu, Yuji Nobuoka, Yoshimichi Okayama
Objective To investigate mechanisms of anaphylaxis in patients with osteoarthritis (OA) of knee and hip after diclofenac etalhyaluronate (product name: JOYCLU® [JCL]) intra-articular injection, and to determine the utility of tests to investigate the mechanism involved. Methods In this observational study in Japan, patients aged ≥20 years with knee or hip OA who received JCL intra-articular injection
-
The Relationship between Locomotive Syndrome and Depression in Young Chinese College Students Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-18 Yixuan Ma, Xinze Wu, Weihao Hong, Yuxiang Ning, Xiao Zhou, Shaoshuai Shen, Bing Zhang
Objectives This study investigates the relationship between locomotive syndrome (LS) and mental disorder (depression) in young Chinese college students. Methods Our study population (n = 165; mean age of 19.82 ±1.90 years) comprises college student residents at Tsinghua University in Beijing, China. Three screening methods were used to evaluate LS: 25-question Geriatric Locomotive Function Scale (GLFS-25)
-
The Importance of Small Joint Involvement in Oligoarticular Juvenile Idiopathic Arthritis Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-14 Melike Mehveş Kaplan, Zahide Ekici Tekin, Vildan Güngörer, Elif Çelikel, Tuba Kurt, Merve Cansu Polat, Müge Sezer, Nilüfer Tekgöz, Cüneyt Karagöl, Serkan Coşkun, Nimet Öner, Banu Çelikel Acar
Objectives: Our study aimed to evaluate the relationship of small joint involvement with demographic, clinical, and laboratory findings and to determine its possible effects on prognosis. Methods: This retrospective observational study was conducted in patients diagnosed with oJIA in the pediatric rheumatology department of our hospital between April 2009-September 2022. The relationship between small
-
Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-11 Hideto Kameda, Kunihiro Yamaoka, Yuji Yamanishi, Masahiro Tada, Ryuji Koike, Ayako Nakajima, Mie Fusama, Takao Fujii
Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for the treatment of RA in Japan in 1999 at a recommended dose of 6–8 mg/week. The approved maximum dose of MTX has been 16 mg/week since February 2011 when MTX was approved as a first-line drug in the treatment of RA. Recent evidence of MTX-polyglutamate concentration in the red
-
Effect of extended dosing interval of anti-TNF-alpha NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-07 Tsutomu Takeuchi,Megumi Nakanishi,Masafumi Kawanishi,Hironori Yamasaki,Yoshiya Tanaka
OBJECTIVE To evaluate the effect of extended dosing interval on the efficacy and safety of ozoralizumab in patients with rheumatoid arthritis (RA). METHODS In a long-term extension study (HOSHIZORA trial) for patients who had completed a phase II/III study with methotrexate (MTX) or a phase III study without MTX, the dosing interval of ozoralizumab was allowed to extend from every 4 weeks (Q4W) to
-
MRI screening for osteonecrosis of the femoral head after COVID-19. Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-07 Kazuma Takashima,Makoto Iwasa,Wataru Ando,Keisuke Uemura,Hidetoshi Hamada,Hirokazu Mae,Yuki Maeda,Nobuhiko Sugano
OBJECTIVES Systemic steroid administration has been suggested for the treatment of coronavirus disease 2019 (COVID-19), but the occurrence of osteonecrosis of the femoral head (ONFH) was one of the concerns for this treatment. This study aimed to use magnetic resonance imaging (MRI) to assess the incidence of ONFH after treatment COVID-19. METHODS The study included 41 patients who were hospitalized
-
Locomotive syndrome and depressive symptoms: A cross-sectional study in middle-aged women Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-06 Michitaka Kato, Etsuko Ozaki, Daisuke Matsui, Wataru Nakano, Satoko Nakano, Sintaro Ono, Kazuya Kito, Teruhide Koyama
Objective Evidence for an association between locomotive syndrome (LS) and depression is lacking in middle-aged women. This study aimed to investigate the relationship between LS severity and depressive symptoms in community-dwelling middle-aged women. Methods This cross-sectional study included 1,520 middle-aged women (mean age 52 ± 6 years). LS severity was evaluated using the 25-question Geriatric
-
Optimal Dose of Intravenous Cyclophosphamide during remission induction therapy in ANCA-associated vasculitis: a retrospective cohort study of J-CANVAS Mod. Rheumatol. (IF 2.2) Pub Date : 2023-10-06 Hideaki Sofue, Takashi Kida, Aiko Hirano, Satoshi Omura, Masatoshi Kadoya, Daiki Nakagomi, Yoshiyuki Abe, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Kiyoshi Matsui, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Mayuko
Objectives To identify the optimal dose of intravenous cyclophosphamide (IVCY) for induction therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods We retrospectively assessed patients with AAV who received IVCY every 2–3 weeks during the remission induction phase. The associations of the IVCY dose with infection-free survival and relapse-free survival were analysed using
-
Gender differences in patient experience in idiopathic inflammatory myopathies: Sub analysis from the COVAD dataset. Mod. Rheumatol. (IF 2.2) Pub Date : 2023-09-28 Akira Yoshida,Minchul Kim,Masataka Kuwana,Naveen Ravichandran,Ashima Makol,Parikshit Sen,James B Lilleker,Vishwesh Agarwal,Sinan Kardes,Jessica Day,Marcin Milchert,Mrudula Joshi,Tamer Gheita,Babur Salim,Tsvetelina Velikova,Abraham Edgar Gracia-Ramos,Ioannis Parodis,Elena Nikiphorou,Tulika Chatterjee,Ai Lyn Tan,Arvind Nune,Lorenzo Cavagna,Miguel A Saavedra,Samuel Katsuyuki Shinjo,Nelly Ziade,Johannes
OBJECTIVES We aimed to investigate gender-based differences in idiopathic inflammatory myopathies (IIMs), with a particular focus on patient-reported outcomes, utilizing data obtained through the international COVID-19 vaccination in autoimmune disease (COVAD) e-survey. METHODS Patient-reported outcomes including fatigue, pain, and physical function were extracted from the COVAD database and compared
-
The effect of intra-articular steroid injection on the cartilage and tendon thicknesses in juvenile idiopathic arthritis. Mod. Rheumatol. (IF 2.2) Pub Date : 2023-09-27 Nihal Şahin,Sümeyra Özdemir Çiçek,Ayşenur Paç Kısaarslan,İsmail Dursun,Muammer Hakan Poyrazoğlu,Ruhan Düşünsel
BACKGROUND AND AIM Intra-articular corticosteroid injection (IACI) is a safe first-line or adjunct therapy that can be used in any subtype of juvenile idiopathic arthritis (JIA). However, limited studies evaluated the effect of IACI on cartilage. As a result, our study aimed to examine the distal femoral cartilage thickness of patients with JIA who received IACI to the knee joint using ultrasound imaging
-
Extraction of Characteristic Serum MicroRNAs and Prediction of Target Genes in IgG4-related Dacryoadenitis and Sialadenitis Mod. Rheumatol. (IF 2.2) Pub Date : 2023-09-25 Motohisa Yamamoto, Tomonao Tanaka, Satsuki Aochi, Masaaki Uehara, Ryuta Kamekura, Ken-ichi Takano
Objectives To identify the specific microRNAs (miRNAs) in IgG4-related dacryoadenitis and sialadenitis (IgG4-DS) and predict the targeted genes. Methods MiRNAs in the serum of 9 patients with IgG4-DS, 3 patients with primary Sjögren’s syndrome, and 3 healthy controls were analyzed using the human miRNA chip, and miRNAs that exhibited significant fluctuation in expression in IgG4-DS patients were extracted
-
Prevalence, patient characteristics and treatment patterns among SLE-PAH patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan Mod. Rheumatol. (IF 2.2) Pub Date : 2023-09-25 Tatsuya Atsumi, Jin Yu Tan, Ashley Pei-Chun Chiang, Dae Young Yu, Yogeshwar Makanji, David Bin-Chia Wu, Jeremy Casorso, Mahsa Kouhkamari, Sooyeol Lim
Objective Real-world evidence regarding prevalence, patient characteristics and treatment patterns for pulmonary arterial hypertension (PAH) related to systemic lupus erythematosus (SLE) in Japan is limited. Methods We conducted a retrospective study analysing Japan’s Medical Data Vision (MDV) database from April-2008 to September-2020. Prevalence, incidence, patient characteristics, treatment patterns
-
Heating of the neck or elbows alleviates Raynaud’s phenomenon but has different effects on different types of patients with systemic sclerosis Mod. Rheumatol. (IF 2.2) Pub Date : 2023-09-12 Yoshihito Shima, Akane Watanabe, Nobuto Inoue, Tetsuya Maruyama, Eiji Kunitomo, Atsushi Kumanogoh
Objectives We previously reported that heating of the neck or elbows alleviated Raynaud’s phenomenon in patients with systemic sclerosis and upregulated capillary extension factor angiopoietin-1 (Angpt-1) in the fingertips. Here, we investigated which cases responded better to the effect of heating of the neck or elbows. Methods The pre- to post-heating change in the visual analogue scale for Raynaud’s
-
The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis Mod. Rheumatol. (IF 2.2) Pub Date : 2023-09-11 Yoshiya Tanaka, Tatsuya Atsumi, Masato Okada, Tomoya Miyamura, Tomonori Ishii, Susumu Nishiyama, Ryutaro Matsumura, Atsushi Kawakami, Nobuya Hayashi, Gabriel Abreu, Sule Yavuz, Catharina Lindholm, Hussein Al-Mossawi, Tsutomu Takeuchi
Objectives Evaluate the long-term safety and tolerability of anifrolumab 300 mg, alongside standard therapy, in patients from Japan with systemic lupus erythematosus (SLE) in the TULIP-LTE trial (NCT02794285). Methods TULIP-LTE was a 3-year, randomized, double-blind, placebo-controlled long-term extension (LTE) of the TULIP trials. The primary safety outcome included serious adverse events (SAEs) and
-
Frozen shoulder. An overview of pathology and biology with hopes to novel drug therapies. Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-26 Kazuya Tamai, Junichiro Hamada, Yuichi Nagase, Masahiko Morishige, Masashi Naito, Hideaki Asai, Sakae Tanaka
Frozen shoulder (FS) is a common disorder characterized by spontaneous onset of shoulder pain accompanied by progressive loss of range-of-motions. The cause of FS is still unclear and radical therapy has not been established. With the final aim of preventing or curing FS at an earlier stage, we reviewed the pathological and biological features of this disease. Many studies indicate that the main pathology
-
Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: post-hoc subgroup analyses of the Japanese real-world observational “ORIGAMI” study Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-24 Masayoshi Harigai, Eiichi Tanaka, Eisuke Inoue, Naoto Tamura, Kenta Misaki, Takanori Azuma, Shintaro Hirata, Fuminori Hirano, Yoshinori Taniguchi, Masaki Mitsuhashi, Masahiro Kondo, Motohiro Oribe, Kazutoshi Aoki, Michiaki Kadode, Katsuki Tsuritani, Hisashi Yamanaka
Objectives To address improvements in quality of life (QOL), we analysed the relative contributions of factors to EuroQol 5 Dimensions (EQ-5D) in abatacept-treated rheumatoid arthritis (RA) patients in the ORIGAMI study. Methods Patients who were evaluable for disease activity through to Week 52 in the ORIGAMI study were divided into those achieving Simplified Disease Activity Index-remission/low disease
-
Assessment of clinical and radiological characteristics of Japanese patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-24 Yu Mori, Takuya Izumiyama, Hiroshi Okuno, Munenori Watanuki, Ryuichi Kanabuchi, Shinichiro Yoshida, Jun Iwatsu, Naoko Mori, Toshimi Aizawa
Objective This study aimed to analyse the radiological characteristics and clinical diversity of Japanese patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, a heterogeneous disorder. Methods Radiographs and clinical information from 115 Japanese patients (female/male: 81/34; mean age at onset: 48.7 years) diagnosed with SAPHO syndrome between January 2007 and December
-
Association of bisphosphonate with bone loss and pain-related behavior in an adjuvant-induced osteoporosis model Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-22 Norihiro Mayumi, Hiroki Wakabayashi, Gaku Miyamura, Akihiro Sudo
Objectives: Osteoporosis animal models are used extensively to determine the mechanisms of disease pathology and identify potential biological targets. The study aimed to establish a bone loss model, identify pain-related behavior in neighboring joints using an adjuvant-induced osteoporosis (AO) model, and examine the therapeutic effect of bisphosphonates (BP). Methods: Complete Freund’s adjuvant (CFA)
-
Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI) Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-22 Yoshiya Tanaka, Toshiya Takahashi, Hubert van Hoogstraten, Naoto Kato, Hideto Kameda
Objective The aim of this study is to investigate the effects of sarilumab on unacceptable pain [UP; visual analogue scale (VAS) >40 mm] and inflammation in patients with moderately-to-severely active rheumatoid arthritis. Methods In this post hoc analysis of the KAKEHASI study, 243 patients received methotrexate with sarilumab 150 or 200 mg or placebo every other week, over 52 weeks. The proportion
-
Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update – secondary publication Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-21 Ken-ei Sada, Kenji Nagasaka, Shinya Kaname, Eishu Nango, Kan Kishibe, Hiroaki Dobashi, Keiju Hiromura, Tamihiro Kawakami, Masashi Bando, Takashi Wada, Koichi Amano, Yohko Murakawa, Masayoshi Harigai
Objective To revise the 2017 clinical practice guidelines (CPG) for the management of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) to reflect advancements in the field. Methods Similar to the 2017 CPG, the Grading of Recommendations, Assessment, Development, and Evaluation system was adopted for this revision. The intended users of this CPG include patients diagnosed with
-
Variables for differential diagnosis of familial Mediterranean fever: multiple correspondence analysis of a large Japanese cohort Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-12 Dai Kishida, Akinori Nakamura, Masahide Yazaki, Ayako Tsuchiya-Suzuki, Takanori Ichikawa, Yasuhiro Shimojima, Yoshiki Sekijima
Objectives: We investigated differential diagnoses that should be noted with familial Mediterranean fever (FMF) and useful variables for differentiation in a large Japanese cohort. Methods: Patients aged ≥13 years who were clinically suspected of having FMF by Livneh criteria were studied 1 year after MEFV genetic testing. Patients ultimately diagnosed with other diseases were studied, and the association
-
Non-infectious uveitis referred for pediatric rheumatologic assessment and management: a Portuguese retrospective study Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-10 Hugo José Barreiro Gonçalves, Carla Zilhão, Vasco Miranda, Sérgio Alves, Liane Correia
Background Pediatric uveitis poses challenges in diagnosis and treatment due to asymptomatic or oligosymptomatic presentations and high rates of intraocular complications. Objectives This study aimed to characterize clinical manifestations and treatment approaches of pediatric uveitis patients in a northern Portuguese tertiary hospital. Methodology A retrospective study was conducted involving forty-one
-
Challenges faced by nurses engaged in rheumatology care in Japan Mod. Rheumatol. (IF 2.2) Pub Date : 2023-08-04 Mie Fusama, Hideko Nakahara, Misuzu Gregg, Yuriko Kuroe, Yukitomo Urata, Kimito Kawahata, Yutaka Kawahito, Masayo Kojima, Takahiko Sugihara, Motomu Hashimoto, Takako Miyamae, Atsuko Murashima, Masaaki Mori, Nobuyuki Yajima, Toshihiro Matsui
Objectives This study aimed to identify the challenges faced by nurses engaged in rheumatology care in Japan. Methods We conducted a questionnaire survey of nurses in Japan in 2020 on challenges experienced in rheumatology care. The participants were nurses certified by the Japan Rheumatism Foundation. Participants’ answers were coded and categorized based on relevant phrases and words. Content analysis